NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

- He made reference to CVM rushing to release TLD without a supporting paper and getting beaten down even though they have some data and results that are actually, potentially, positive; said now they are stuck in a quiet period until scientific publication just like NWBO, but their quiet period is marred by a muddy TLD release. He stressed that the goal is approval, not getting TLD to market, and that rushing to release TLD does not get them to approval any faster. I know what you’re thinking and no, I did not take this as DI equivocating muddy CVM data to muddy NWBO data. I think it has more to do with how they are analyzing the data, which leads me to:

Way to go DI!

Problem is, CVM clearly missed the trial primary endpoint and the subgroup analysis they are hyping is what is called exploratory. And a pointless one at that as you can not identify low risk patients (the population it worked in) at the time you must treat them. And still no true TLD (the comparison between the 2 main trial arms).

Both companies have taken over a 50% hit from the highs when TLD was expected. CVM for hyping a failure, NWBO for raising crickets.